Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Apr '12
|
Lord Glendonbrook
|
|
Astrazeneca / LSE:AZN.L |
£2,666.50
|
£10,244.00
|
284.17%
|
£268,921.81
|
Apr '10
|
Baroness Noakes
|
|
Astrazeneca / LSE:AZN.L |
£2,938.00
|
£10,244.00
|
248.67%
|
£244,070.80
|
Mar '14
|
Viscount Eccles
|
|
Astrazeneca / LSE:AZN.L |
£3,876.50
|
£10,244.00
|
164.26%
|
£184,981.30
|
Dec '16
|
Lord Burns
|
|
Astrazeneca / LSE:AZN.L |
£4,116.00
|
£10,244.00
|
148.88%
|
£174,217.69
|
Feb '11
|
Lord Wasserman
|
|
Johnson & Johnson / NYQ:JNJ |
£60.93
|
£143.58
|
135.65%
|
£164,953.23
|
Jan '13
|
Lord Sassoon
|
|
Johnson & Johnson / NYQ:JNJ |
£72.69
|
£143.58
|
97.52%
|
£138,266.61
|
Sep '16
|
Lord Gadhia
|
|
Astrazeneca / LSE:AZN.L |
£5,099.00
|
£10,024.00
|
96.59%
|
£137,611.30**
|
May '18
|
Lord Grabiner
|
|
Astrazeneca / LSE:AZN.L |
£5,417.00
|
£10,244.00
|
89.11%
|
£132,375.85
|
May '11
|
Lord Glendonbrook
|
|
Novartis / NYQ:NVS |
£54.04
|
£96.77
|
79.07%
|
£125,346.91
|
Aug '14
|
Lord Carter of Coles
|
|
Johnson & Johnson / NYQ:JNJ |
£100.16
|
£161.55
|
61.29%
|
£112,904.35**
|
Apr '17
|
Lord Donoughue
|
|
Novartis / NYQ:NVS |
£66.05
|
£96.77
|
46.51%
|
£102,559.66
|
Feb '21
|
Lord Etherton
|
|
Astrazeneca / LSE:AZN.L |
£7,422.00
|
£10,244.00
|
38.02%
|
£96,615.47
|
May '20
|
Lord Deighton
|
|
Astrazeneca / LSE:AZN.L |
£8,361.00
|
£11,236.00
|
34.39%
|
£94,070.09**
|
May '11
|
Lord Glendonbrook
|
|
Pfizer / NYQ:PFE |
£19.54
|
£25.77
|
31.85%
|
£92,296.63
|
Nov '23
|
Lord Mance
|
|
Eli Lilly Co / VIE:LLYC.VI |
£557.00
|
£730.00
|
31.06%
|
£91,741.47
|
Jun '21
|
Lord Morse
|
|
Astrazeneca / LSE:AZN.L |
£8,005.00
|
£10,244.00
|
27.97%
|
£89,579.01
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Johnson & Johnson / NYQ:JNJ |
£133.45
|
£157.98
|
18.38%
|
£82,866.99**
|
Jul '16
|
Lord Lloyd-Webber
|
|
Johnson & Johnson / NYQ:JNJ |
£122.64
|
£143.58
|
17.07%
|
£81,952.06
|
Apr '21
|
Lord Farmer
|
|
Glaxosmithkline / NYQ:GSK |
£36.65
|
£40.88
|
11.54%
|
£78,079.12**
|
Apr '21
|
Baroness Deech
|
|
Novartis / NYQ:NVS |
£88.38
|
£96.77
|
9.49%
|
£76,645.17
|
Oct '20
|
Lord Taverne
|
|
Glaxosmithkline / NYQ:GSK |
£37.57
|
£40.95
|
9.00%
|
£76,297.58**
|
May '24
|
Lord Goldsmith
|
|
Abbvie / NYQ:ABBV |
£160.81
|
£171.52
|
6.66%
|
£74,662.03
|
May '23
|
Lord Leitch
|
|
Astrazeneca / LSE:AZN.L |
£11,820.00
|
£12,340.00
|
4.40%
|
£73,079.53**
|
Apr '24
|
Lord Mendoza
|
|
Eli Lilly / NYQ:LLY |
£731.33
|
£757.54
|
3.58%
|
£72,508.71
|
Apr '23
|
Lord Grabiner
|
|
Novartis / NYQ:NVS |
£95.80
|
£96.77
|
1.01%
|
£70,708.76
|
Nov '23
|
Lord Mance
|
|
Astrazeneca / LSE:AZN.L |
£10,230.00
|
£10,244.00
|
0.14%
|
£70,095.80
|
Jan '24
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£251.85
|
£246.70
|
-2.04%
|
£68,568.59
|
Apr '17
|
Lord Leigh of Hurley
|
|
Roche / EBS:ROG.SW |
£255.80
|
£246.70
|
-3.56%
|
£67,509.77
|
Dec '16
|
Lord Burns
|
|
Glaxosmithkline / NYQ:GSK |
£37.39
|
£33.43
|
-10.59%
|
£62,586.26
|
Feb '16
|
Lord Lloyd-Webber
|
|
Pfizer / NYQ:PFE |
£29.02
|
£25.77
|
-11.21%
|
£62,154.65
|
Jan '20
|
Lord Gadhia
|
|
Glaxosmithkline / NYQ:GSK |
£46.50
|
£40.95
|
-11.94%
|
£61,645.16**
|
May '23
|
Lord Fink
|
|
Astrazeneca / LSE:AZN.L |
£11,774.00
|
£10,244.00
|
-12.99%
|
£60,903.69
|
May '23
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£165.03
|
£143.58
|
-13.00%
|
£60,901.66
|
May '23
|
Lord Londesborough
|
|
Astrazeneca / LSE:AZN.L |
£11,924.00
|
£10,244.00
|
-14.09%
|
£60,137.54
|
Apr '22
|
Lord Cromwell
|
|
Johnson & Johnson / NYQ:JNJ |
£179.90
|
£154.37
|
-14.19%
|
£60,066.15**
|
May '23
|
Lord Reay
|
|
Sanofi / NMS:SNY |
£55.11
|
£47.22
|
-14.32%
|
£59,978.23**
|
Apr '24
|
Lord Balfe
|
|
Astrazeneca / LSE:AZN.L |
£12,024.00
|
£10,244.00
|
-14.80%
|
£59,637.39
|
Apr '10
|
Lord Levene of Portsoken
|
|
Glaxosmithkline / NYQ:GSK |
£39.38
|
£33.43
|
-15.11%
|
£59,423.56
|
Apr '10
|
Baroness Noakes
|
|
Glaxosmithkline / NYQ:GSK |
£39.49
|
£33.43
|
-15.35%
|
£59,258.04
|
May '24
|
Lord Goldsmith
|
|
Astrazeneca / LSE:AZN.L |
£12,156.00
|
£10,244.00
|
-15.73%
|
£58,989.80
|
Aug '16
|
Lord Lloyd-Webber
|
|
Eli Lilly / NYQ:LLY |
£80.55
|
£67.15
|
-16.64%
|
£58,355.06**
|
Apr '21
|
Lord Grabiner
|
|
Roche / EBS:ROG.SW |
£309.65
|
£246.70
|
-20.33%
|
£55,769.42
|
Aug '20
|
Lord Reay
|
|
Roche / EBS:ROG.SW |
£315.05
|
£249.80
|
-20.71%
|
£55,502.30**
|
Mar '17
|
Lord Lloyd-Webber
|
|
Glaxosmithkline / NYQ:GSK |
£42.31
|
£33.43
|
-20.99%
|
£55,308.44
|
May '11
|
Lord Glendonbrook
|
|
Glaxosmithkline / NYQ:GSK |
£42.78
|
£33.43
|
-21.86%
|
£54,700.80
|
May '24
|
Lord Balfe
|
|
Glaxosmithkline / NYQ:GSK |
£44.02
|
£33.43
|
-24.06%
|
£53,159.93
|
Jan '13
|
Lord Sassoon
|
|
Glaxosmithkline / NYQ:GSK |
£44.75
|
£33.43
|
-25.30%
|
£52,292.74
|
Mar '14
|
Baroness Eccles of Moulton
|
|
Glaxosmithkline / NYQ:GSK |
£53.43
|
£33.43
|
-37.43%
|
£43,797.49
|
Jul '18
|
Lord Glendonbrook
|
|
Bayer / GER:BAYN.DE |
£95.26
|
£18.87
|
-80.19%
|
£13,866.26
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.